- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05927441
DragonFly EU Pivotal Study
Safety and Performance Evaluation Study of DragonFly System for Mitral Regurgitation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, multicentric clinical investigation.
Subjects to be included in this clinical investigation suffer from symptomatic chronic moderate-to-severe (3+) or severe (4+) DMR with high or prohibitive surgical risk judged by a local investigation site's heart team and symptomatic moderate-to- severe (3+) or severe (4+) functional mitral regurgitation subjects who remained clinically symptomatic after adequate treatment.
Local heart teams must include at a minimum a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease. After signing the informed consent form (ICF), a subject will be enrolled and treated with the DragonFlyTM Transcatheter Mitral Valve Repair System (Valgen Medtech, Hangzhou).
The CE-DMR cohort clinical investigation will be assessed at the following intervals: implant, before discharge, 30 days, 6 months and annually for 5 years. Group sequential design analysis is planned based on an adaptive design to assess whether the primary endpoint will be met. If the primary endpoint is not met at the interim analysis, then it will be re-analyzed for 160 patients when all subjects in Europe/Canada complete 12 months follow-up.
The CE-FMR cohort clinical investigation will be assessed at the following intervals: implant, before discharge, 30 days, 6 months and annually for 5 years. An adaptive design with sample size re-estimation will be incorporated. The primary endpoint will be assessed at the interim analysis. If the conditional power falls within the promising zone (38-80%), then the sample size will be re-estimated to maintain at least 80% power. Then the primary endpoint will be evaluated once the 12-month follow-up is completed with the larger sample size (not less than 165).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shuangjie Li
- Phone Number: +8617756106609
- Email: shuangjie.li@valgenmed.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years old
- New York Heart Association (NYHA) Class II-IV
- Moderate to severe (3+) or severe (4+) chronic DMR determined by transthoracic echocardiography (For DMR cohort)
- Symptomatic FMR ≥ 3+ due to ischemic or non-ischemic cardiomyopathy (For FMR cohort)
- Transseptal catheterization and femoral vein access are determined to be feasible
- Subjects have been informed of the nature of the study, understand the purpose of the clinical trial, voluntarily participate in the study, and sign the ICF
Exclusion Criteria:
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Other severe heart valve diseases requiring intervention
- Prior mitral valve leaflet surgery (prior annuloplasty ring not excluded) or previous transcatheter mitral valve intervention
- Acute myocardial infarction occurred within 4 weeks, or untreated severe coronary artery stenosis requiring revascularization
- Any cardiovascular intervention within 30 days or cardiac surgery within 6 months prior to the procedure; or in the judgment of the investigator, the femoral vein cannot accommodate a 25 F catheter or the presence of an inferior vena cava filter would interfere with advancement of the catheter or ipsilateral deep vein thrombosis is present; or the patient's anatomy is not suitable for atrial septal puncture
- Patients in whom TEE or general anesthesia is contraindicated
- End stage heart failure (ACC/AHA stage D); or after heart transplantation; or waiting for a heart transplantation
- Active endocarditis or active rheumatic heart disease; or mitral valve changes due to endocarditis and rheumatic heart valve disease
- History of ischemia cerebrovascular accident in the past 30 days, or severe symptomatic carotid stenosis (ultrasonic examination showed stenosis degree >70%); or carotid stent implantation within 30 days; hemorrhagic cerebrovascular accident occurred within 6 months
- History of acute peptic ulcer or gastrointestinal bleeding within 3 months
- Hemorrhagic disease or coagulation disorder; or contraindicated of antithrombotic drug treatment
- Modified Rankin scale ≥ 4
- Diseases that make the evaluation of treatment difficult (e.g., cancer, severe metabolic disease, psychosis)
- Pregnant or lactating women
- Hemodynamic instability defined as systolic pressure < 90 mmHg without afterload reduction medicine, or cardiogenic shock, or need for an intra-aortic balloon pump, or other hemodynamic support devices
- Active infections requiring current antibiotic therapy (if temporary illness, patients may be enrolled 2 weeks after discontinuation of antibiotics)
- Currently participating in an investigational drug or another device study of which the primary endpoint has not been completed, or it that clinically interferes with the current study endpoints. (Note: extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational study)
- In the judgment of the investigator, the patients' compliance will be poor and could not complete the study as required, or other conditions indicate that the subject is not suitable to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DragonFly Transcatheter Mitral Valve Repair System-DMR
Transcatheter mitral valve repair with the DragonFly System in patients with degenerative mitral regurgitation
|
Edge-to-edge repair with DragonFly System
Other Names:
|
Experimental: DragonFly Transcatheter Mitral Valve Repair System-FMR
Transcatheter mitral valve repair with the DragonFly System in patients with functional mitral regurgitation
|
Edge-to-edge repair with DragonFly System
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment success at 12 months after the procedure for DMR Cohort only
Time Frame: 12 months
|
The rate of the composite endpoint of freedom from all-cause mortality, surgery for mitral valve dysfunction, or MR > 2+ at 12 months.
|
12 months
|
Freedom from all-cause mortality, or hospitalization for heart failure events at 12 months after the procedure for FMR Cohort only
Time Frame: 12 months
|
Freedom from all-cause mortality, or hospitalization for heart failure events at 12 months after the procedure for FMR Cohort only
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francesco Maisano, Ospedale San Raffaele
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DJ/TD/08CC-01E
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Valve Insufficiency
-
Abbott Medical DevicesCompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With InsufficiencyJapan
-
Abbott Medical DevicesRecruitingCardiovascular Diseases | Heart Valve Diseases | Mitral Regurgitation | Mitral Valve Insufficiency | Valve Disease, Heart | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
Abbott Medical DevicesCompletedMitral Regurgitation | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral InsufficiencyUnited States
-
4C Medical Technologies, Inc.RecruitingMitral Regurgitation | Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Mitral IncompetenceUnited States
-
Edwards LifesciencesRecruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve DiseaseUnited States, Canada, Switzerland, Germany
-
Edwards LifesciencesActive, not recruitingMitral Regurgitation | Mitral Insufficiency | Mitral Repair | Mitral Valve | Annuloplasty | Edwards CardiobandSwitzerland, Germany, Italy
-
Assistance Publique - Hôpitaux de ParisEuropean Association of Cardiovascular ImagingNot yet recruitingAortic Valve Stenosis | Aortic Valve Disease | Heart Valve Diseases | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Tricuspid Valve Insufficiency | Mitral Valve Disease | Tricuspid Valve Disease | Mitral Valve Insufficiency and... and other conditionsFrance
Clinical Trials on DragonFly Transcatheter Mitral Valve Repair System
-
Hangzhou Valgen Medtech Co., LtdEnrolling by invitationDegenerative Mitral Valve DiseaseChina
-
Hangzhou Valgen Medtech Co., LtdRecruitingMitral Regurgitation FunctionalChina
-
Hangzhou Valgen Medtech Co., LtdEnrolling by invitationTricuspid RegurgitationChina
-
Hangzhou Valgen Medtech Co., LtdEnrolling by invitation
-
Hangzhou Valgen Medtech Co., LtdRecruitingTricuspid RegurgitationChina
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingTricuspid RegurgitationChina
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Michele De BonisCompletedMitral Valve RegurgitationItaly
-
Shanghai Zhongshan HospitalNot yet recruitingMitral Regurgitation
-
Shanghai Shenqi Medical Technology Co., LtdActive, not recruitingFunctional Mitral RegurgitationChina